CapsoVision Appoints Financial Veteran to Fuel Growth of AI-Powered Endoscopy

San Clemente, CA – November 10, 2025 – CapsoVision, Inc. (NASDAQ: CV), a medical technology company specializing in advanced capsule endoscopy, today announced the appointment of David Garcia as Senior Vice President of Finance. The move signals an ambitious growth trajectory for the company, building on recent successes and positioning CapsoVision to capitalize on the increasing demand for non-invasive gastrointestinal diagnostics.

Garcia brings over 20 years of financial leadership experience to CapsoVision, including a proven track record of successfully navigating companies through initial public offerings and mergers & acquisitions. Most recently, he served as Vice President of Financial Planning & Analysis at Matterport, where he played a critical role in the company’s public listing and subsequent strategic transactions.

“We are thrilled to welcome David to the CapsoVision team,” said Johnny Wang, CEO of CapsoVision. “His deep understanding of capital markets, strategic financial planning, and operational execution will be invaluable as we continue to advance our development pipeline and execute on our growth strategy. David's expertise will be crucial in achieving our clinical and corporate milestones.”

A Strategic Hire Amidst Rapid Growth

CapsoVision’s appointment of Garcia comes at a pivotal moment for the company. Having successfully completed its IPO in July 2025, CapsoVision is poised for expansion, driven by its innovative approach to gastrointestinal diagnostics. The company’s flagship product, CapsoCam Plus®, is a wireless, ingestible capsule endoscope that provides high-quality images of the small bowel, offering a comfortable and convenient alternative to traditional colonoscopies. CapsoVision is also developing CapsoCam Colon™, an AI-powered system designed for non-invasive colon imaging and polyp detection, expanding its diagnostic capabilities into a significant new market segment.

“The market for non-invasive GI diagnostics is expanding rapidly,” notes a medical device industry analyst who requested anonymity. “Patients are increasingly seeking more comfortable and convenient alternatives to traditional procedures. CapsoVision’s technology, combined with a strong financial leader like Garcia, positions them well to capture a significant share of this growing market.”

Leveraging IPO and M&A Expertise

Garcia’s experience at Matterport is particularly relevant for CapsoVision. Leading the financial planning for Matterport’s IPO, a transaction completed via a SPAC merger, honed his expertise in navigating the complexities of public markets and investor relations. This experience is expected to be critical as CapsoVision seeks to raise additional capital to fund its growth initiatives and expand its product pipeline.

“Going public is a significant undertaking,” explains a former CFO of a publicly traded medtech company, speaking anonymously. “It requires meticulous financial planning, rigorous regulatory compliance, and effective communication with investors. Garcia’s experience at Matterport will be a tremendous asset to CapsoVision.”

Beyond the IPO, Garcia’s involvement in Matterport’s recent acquisition underscores his understanding of M&A transactions, including financial due diligence, deal structuring, and integration. This expertise may prove valuable as CapsoVision explores strategic partnerships or acquisitions to accelerate its growth and expand its technological capabilities.

AI-Powered Diagnostics: A Growing Trend

CapsoVision’s commitment to artificial intelligence is a key differentiator in the increasingly competitive GI diagnostics market. The company’s CapsoCam Colon™ system leverages AI algorithms to automatically detect polyps and other abnormalities, enhancing diagnostic accuracy and efficiency. This focus on AI aligns with the broader trend of incorporating advanced technologies into medical devices to improve patient outcomes and reduce healthcare costs.

“AI is transforming the medical device industry,” says a digital health consultant who requested anonymity. “AI-powered diagnostics can help physicians make more informed decisions, personalize treatment plans, and improve patient outcomes. CapsoVision’s commitment to AI positions them at the forefront of this innovation.”

Financial Strength and Strategic Vision

CapsoVision’s financial performance has been strong since its IPO. The company’s stock price has increased by 39% year-to-date, reflecting investor confidence in its growth potential. With Garcia at the helm of its financial operations, CapsoVision is well-positioned to continue its growth trajectory and capitalize on the expanding market for non-invasive GI diagnostics.

“We are confident that David’s leadership will be instrumental in achieving our long-term goals,” added Wang. “He is a strategic thinker, a proven financial leader, and a great cultural fit for our team. We are excited to have him on board.”

The appointment of David Garcia marks a significant step forward for CapsoVision, strengthening its financial foundation and positioning it for continued success in the rapidly evolving landscape of gastrointestinal diagnostics. The company’s commitment to innovation, coupled with Garcia’s financial expertise, is expected to drive significant growth and create value for shareholders in the years to come.